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Abstract
We previously reported that lysophosphatidic acid (LPA) inhibits the neuronal differentiation of human
embryonic stem cells (hESC). We extended these studies by analyzing LPA's effects on the expansion of
neural stem/ progenitor cells (NS/PC) derived from hESCs and human induced pluripotent stem cells
(iPSC), and we assessed whether data obtained on the neural differentiation of hESCs were relevant to
iPSCs. We showed that hESCs and iPSCs exhibited comparable mRNA expression profiles of LPA
receptors and producing enzymes upon neural differentiation. We demonstrated that LPA inhibited the
expansion of NS/PCs of both origins, mainly by increased apoptosis in a Rho/Rho-associated kinase
(ROCK)-dependent mechanism. Furthermore, LPA inhibited the neuronal differentiation of iPSCs. Lastly,
LPA induced neurite retraction of NS/ PC-derived early neurons through Rho/ROCK, which was
accompanied by myosin light chain (MLC) phosphorylation. Our data demonstrate the consistency of LPA
effects across various sources of human NS/PCs, rendering hESCs and iPSCs valuable models for
studying lysophospholipid signaling in human neural cells. Our data also highlight the importance of the
Rho/ROCK pathway in human NS/ PCs. As LPA levels are increased in the central nervous system (CNS)
following injury, LPA-mediated effects on NS/ PCs and early neurons could contribute to the poor
neurogenesis observed in the CNS following injury.

Disciplines
Medicine and Health Sciences

Publication Details
Frisca, F., Crombie, D. E., Dottori, M., Goldshmit, Y. & Pebay, A. (2013). Rho/ROCK pathway is essential to
the expansion, differentiation, and morphological rearrangements of human neural stem/progenitor cells
induced by lysophosphatidic acid. Journal of Lipid Research, 54 (5), 1192-1206.

This journal article is available at Research Online: https://ro.uow.edu.au/ihmri/1166

Supplemental Material can be found at:
http://www.jlr.org/content/suppl/2013/03/04/jlr.M032284.DC1
.html

Rho/ROCK pathway is essential to the expansion,
differentiation, and morphological rearrangements
of human neural stem/progenitor cells induced by
lysophosphatidic acid
Frisca Frisca,* Duncan E. Crombie,*,† Mirella Dottori,§ Yona Goldshmit,†,** and Alice Pébay1,*,†

Abstract We previously reported that lysophosphatidic
acid (LPA) inhibits the neuronal differentiation of human
embryonic stem cells (hESC). We extended these studies by
analyzing LPA’s effects on the expansion of neural stem/
progenitor cells (NS/PC) derived from hESCs and human
induced pluripotent stem cells (iPSC), and we assessed
whether data obtained on the neural differentiation of
hESCs were relevant to iPSCs. We showed that hESCs and
iPSCs exhibited comparable mRNA expression profiles of
LPA receptors and producing enzymes upon neural differentiation. We demonstrated that LPA inhibited the expansion
of NS/PCs of both origins, mainly by increased apoptosis
in a Rho/Rho-associated kinase (ROCK)-dependent mechanism. Furthermore, LPA inhibited the neuronal differentiation of iPSCs. Lastly, LPA induced neurite retraction of NS/
PC-derived early neurons through Rho/ROCK, which was
accompanied by myosin light chain (MLC) phosphorylation. Our data demonstrate the consistency of LPA effects
across various sources of human NS/PCs, rendering
hESCs and iPSCs valuable models for studying lysophospholipid signaling in human neural cells. Our data also highlight
the importance of the Rho/ROCK pathway in human NS/
PCs. As LPA levels are increased in the central nervous system (CNS) following injury, LPA-mediated effects on NS/
PCs and early neurons could contribute to the poor neurogenesis observed in the CNS following injury.—Frisca,
F., D. E. Crombie, M. Dottori, Y. Goldshmit, and A. Pébay.
Rho/ROCK pathway is essential to the expansion, differentiation, and morphological rearrangements of human
neural stem/progenitor cells induced by lysophosphatidic
acid. J. Lipid Res. 2013. 54: 1192–1206.
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Lysophosphatidic acid (LPA) is a bioactive lysophospholipid that induces pleiotropic effects in many cell types.
LPA mainly acts through binding to its specific G-proteincoupled receptors LPA1–5, which can couple to Gi, Gq, G12,
and possibly Gs, to modulate specific downstream signaling pathways (1). LPA can also activate the purinergic receptors LPA6/P2Y5 (2), GPR87 (3), and P2Y10 (4), the
transient receptor potential vanilloid receptor 1 cation
channel (TRPV1) (5), and the intracellular peroxisome
proliferator-activator receptor (PPAR) ␥ (6). LPA receptors are expressed in various types of stem cells and demonstrate a differential expression profile across various
cells and tissues (7, 8). LPA can be synthesized both intracellularly and extracellularly by activation of different
enzymes (1); however, it is not yet entirely clear whether
or how intracellular LPA contributes to extracellular signaling. Although LPA can be synthesized extracellularly
by secreted phospholipases A, in particular by the secreted PLA2 group IIA (sPLA2), a major source of extracellular LPA in the central nervous system (CNS) most
probably arises from the activity of the secreted lysophospholipase D enzyme autotaxin (ATX), as this enzyme
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heterogeneity of cell populations, species, LPA receptor
expression profiles, LPA concentration used, and the culture conditions of the cell lines. In rodents, LPA was
reported to stimulate, inhibit, or not affect NS/PC proliferation (13–16). Further, LPA has been shown to be a survival factor, a pro-apoptotic agent or a prodifferentiation
factor of NS/PCs (16–18). Comparably, LPA has also been
described as a proliferative, survival, or prodifferentiation
factor in some neuroblasts but not all (8). It was recently
shown that LPA can induce fetal hydrocephalus in the
mouse by an aberrant activation of Lpa1 on NS/PCs during development (19). LPA also acts through the Rho
pathway to induce morphological rearrangements in neuroblasts and neurons (20–24), including actin polymerization (21) that leads to the formation of retraction fibers,
neurite retraction (21, 25–32), cell rounding (26, 29, 33,
34), cluster compaction (35–38), and growth cone collapse (21, 26, 27).
The study of LPA in human NS/PCs and neurons is still
extremely limited. Although we briefly reported that LPA
inhibits the ability of hESC-derived NS/PCs to form neurospheres, we did not attempt to characterize this biological effect and the signaling pathways associated (39). We
also previously showed that when two-week-old hESC-derived neurospheres were plated onto laminin or fibronectin, LPA inhibited their neuronal differentiation through
the Rho/ROCK and phosphatidylinositol 3-kinase (PI3K)/
Akt pathways (39). This effect was linked to an antidifferentiation effect of LPA, as no modification in apoptosis or
proliferation could be detected on these plated neurospheres (39). Hurst and colleagues, however, reported
that LPA stimulates proliferation and cell-rounding of
hESC-derived neuroepithelium cell line (NEP), a stable
line enriched in hESC-derived NS/PCs and grown under
adherent conditions (40, 41). These variations may be due
to culture conditions or cell origin.
Here and given the potential differences of hESCs and
human iPSCs, we dissected LPA’s effects on the progressive neural differentiation on both types of hPSCs, thus
allowing to directly compare LPA signaling in hESCs and
human iPSCs. Our differentiation protocol allows to assess effects of LPA on NS/PCs during their neural differentiation and on NS/PC-derived neurons. While our
previous study concentrated on the impact of LPA on the
neuronal and glial differentiation of hESC-derived NS/
PCs (39), this current study assessed the effects of LPA at
an earlier stage of neuralization, namely, the expansion
of NS/PCs, from both hESCs and human iPSCs. Further,
we assessed whether the data obtained on the neuronal
and glial differentiation of hESCs were relevant to human iPSCs, allowing us to draw conclusions on the similarity of LPA’s effects across these two different cell types.
Finally, we assessed LPA’s effects on the morphology of
early human neurons derived from NS/PCs. This study
thus provides a comprehensive assessment of the role of
LPA in these various differentiation stages on hESCs and
human iPSCs. Because LPA is released upon inflammation and is involved in neurotrauma and various CNS
diseases (1), appreciating its role on neurogenesis and
LPA modulates human neural progenitor cells
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is found to be expressed in various CNS regions during
development or adulthood, and its activity is modified following various physiopathological events (1). In the CNS,
LPA can target most cell types and plays roles in a variety
of developmental and pathological processes, including
neurogenesis, neuropathic pain, neural injury, schizophrenia, epilepsy, and memory impairment (1).
Neural stem/progenitor cells (NS/PC) have been extensively studied, with the aim of using endogenous and/
or donor NS/PCs to replace neurons and restore circuitry
in a neurodegenerative microenvironment. In theory, human embryonic stem cells (hESC) and human induced
pluripotent stem cells (iPSC) are a great source of cells to
generate NS/PCs and progeny, which could potentially be
used for transplantation and also to provide insight into
human neurogenesis. Although not identical, hESCs and
iPSCs seem very similar, but the extent of the variations
and similarities between the two types of cells remains
open (9). Hence, comparing their differentiation potentials and response to specific signaling molecules is still
required to allow drawing conclusions on whether hESCs
and iPSCs show critical differences. It was previously shown
in hESCs that the bone morphogenetic protein inhibitor
noggin induces neuroectodermal differentiation, as shown
by the expression of SOX2, paired box protein 6, and nestin and a lack of expression of early mesoderm or endoderm markers (10). Once dissected, these colonies are
propagated in suspension in neural basal media (NBM)
supplemented with basic fibroblast growth factor (bFGF)
and epidermal growth factor (EGF), where they aggregate
and form a spherical-like cluster named neurosphere,
which consists of a heterogeneous population of NS/PCs
(10). Neurospheres can be differentiated to give rise to
neurons and glia when plated onto laminin or fibronectin
substrates, respectively. Hence, this differentiation protocol allows the progressive neural patterning of human
pluripotent stem cells (hPSC, noggin stage), efficient generation and expansion of NS/PCs (neurosphere stage),
and subsequent differentiation into early neurons and
glial cells (11). Other protocols of differentiation have
been established for hESCs (12), including protocols that
maintain NS/PCs as a monolayer instead of a neurosphere,
but they are less defined. This overall method allows to
precisely divide the whole differentiation process into defined stages and to efficiently generate human neural progenitors and early neurons, rendering this technique
robust and well defined. These features make this protocol highly useful for the study of fundamental signaling
mechanisms involved in NS/PC multipotency and expansion. Unraveling these mechanisms may allow for better
and more efficient techniques to use human NS/PCs, either endogenous or exogenous, to treat neurodegeneration and inflammation of the CNS by characterizing, for
instance, how the cellular environment modifies NS/PC
fate in term of survival and differentiation.
LPA’s effects on NS/PCs and neuroblasts seem to vary
depending on the origin of the cells (8). These differences might be the consequence of discrepancies in terms
of cell source (different lines and differentiation stages),
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understanding its impact, specifically on NS/PCs and
progeny, is relevant to transplantation work. LPA might
be the environmental cue that is able to modify the behavior of NS/PCs and their derivatives during inflammation after neurotrauma.

MATERIALS AND METHODS
Ethics
All experiments were approved by the Human Research Ethics
Committees of the University of Melbourne (Approvals 0605017
and 0830010).

Reagents

RT-PCR
mRNA was isolated from undifferentiated hPSCs, noggintreated hPSCs, NS/PCs in neurospheres, and monolayers of NS/
PCs using Dynabeads Oligo (dT)25 (Dynabeads). RT-PCR were
conducted using High Capacity cDNA Reverse Transcriptase Kit
(Applied Biosystems), following the manufacturer’s instructions.
A negative control (⫺RT) consisting in the absence of reverse
transcriptase was performed to check the absence of genomic
DNA. qPCR was carried out using TaqMan Universal master mix
(Applied Biosystems) and the 7900HT Fast Real-Time PCR system
(Applied Biosystems) and TaqMan gene expression assays for
LPA1–5 and ATX (Applied Biosystems). TaqMan gene expression
assays for LPA1 (Hs00173500_m1), LPA2 (Hs00173704_m1), LPA3
(Hs00173857_m1), LPA4 (Hs00271072_s1), LPA5 (Hs01051307_
m1), ATX (Hs00196470_m1), PLA2-group IIA (Hs00179898_
m1), ROCK1 (Hs01127699_m1), and ROCK2 (Hs00178154_m1)
were used (Applied Biosystems). The relative quantitation was
achieved by applying the comparative CT method (⌬⌬CT) in
which the mRNA levels were normalized against the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA (TaqMan
gene expression assay Hs99999905_m1) or ␤-actin (Hs99999903_
m1) with LPA5 used as the reference. Q-PCR reaction of the nonreverse-transcribed sample was also conducted for each Taqman
probe above to check the genomic DNA contamination in the
sample and the specificity of the probes.

Immunofluorescence
Following fixation with paraformaldehyde (PFA) 4% for 10
min, cells were blocked in a 10% fetal calf serum-PBS 0.1%
Tween 20 (PBT, 60 min) and immunostained with the following
primary antibodies: mouse anti-␤III-tubulin (Millipore); rabbit
anti-glutamate aspartate transporter (GLAST, Millipore); rabbit
anti-glial fibrillary acidic protein (GFAP, DAKO); mouse antiA2B5 (Millipore); rabbit anti-nestin (Millipore); rabbit antidoublecortin (DCX, Abcam); mouse phospho-myosin light
chain (MLC) 2 (Ser19); and rabbit phospho-cofilin (Ser3)
(77G2, Genesearch). Cells were then immunostained with the
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Cell culture and neural induction of hPSCs
The iPS (Foreskin) 4 clone 1 and clone 2, abbreviated iPS1
and iPS2 (42), and the hESC line ENVY (ES Cell International)
were cultured as described (43, 44). Neuronal induction by noggin (R and D, 500 ng/ml) was performed as described in (11).
Noggin-treated cells were dissected after 14 days and were
further subcultured in suspension in NBM together with bFGF
(Millipore) and EGF (R and D, 20 ng/ml each) to form neurospheres (45).

NS/PC monolayer culture
The monolayer culture of NS/PCs was generated as previously reported (46) with some modifications. Briefly, two-week-old
neurospheres cultured with NBM supplemented with bFGF
and EGF were collected and dissociated by disaggregation with
Trysin-EDTA (Invitrogen). The enzymatic reaction was stopped
using soybean trypsin inhibitor (Sigma). The dissociated cells
were seeded in NBM supplemented with growth factors onto
precoated tissue culture dishes with laminin 1 µg/cm2 (SigmaAldrich) to generate a monolayer of NS/PCs. The medium was
changed every second day. NS/PCs were further passaged with
accutase (Sigma). Medium was changed every second day, and
cells were cultured for three weeks. All experiments were consistently conducted on less than passage 5 monolayered NS/PCs.

Neurosphere formation assay
Noggin-treated cells were harvested after 14 days by dissecting
and further subcultured as neurospheres, in suspension in NBM
together with bFGF and EGF (20 ng/ml each), in the presence
or in the absence of LPA (complete with any inhibitor used),
with medium changed every second day (39). Each condition was
performed in at least eight individual wells and repeated in at
least three independent experiments. Assessment of neurosphere
formation was performed after 7 days.

Neuronal and glial differentiation of neurosphere
After two weeks in suspension, neurospheres cultivated in
NBM with bFGF and EGF were plated as previously described
(11) onto poly-l-lysine/laminin-coated (Sigma, 10 and 5 µg/
ml, respectively) or poly-l-lysine/fibronectin-coated (Millipore,
10 µg/ml) dishes in NBM lacking growth factors to induce
neuronal and glial differentiation, respectively, allowed to attach, and incubated in the presence or in the absence of LPA
(complete with any inhibitor used) for five days (39). For each
type of experiment, after attachment, medium was changed
every second day. Pictures were taken of each individual well
(inverted microscope Olympus IX71 and Cell IR software) following five days in culture. The cells were then fixed with 4%
PFA/PBS.

Quantification of neuron-forming spheres
Quantification was performed by counting the number of
spheres from which neuronal outgrowth was observable (39).
In some cases neurospheres failed to attach, independently of
the treatments, and these floating neurospheres were excluded
from quantification.
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Dilutions of LPA (Sigma-Aldrich, Castle Hill, Australia) were
made in 0.1% fatty acid-free BSA (final concentration 0.01%
BSA; Sigma-Aldrich). Cells were treated with LPA (up to 10 µM),
LPA1/LPA3 antagonists Ki16425 (Sigma-Aldrich, 10 µM), LY294002
(Promega, 10 µM), Y27632 (Biomol, 1 µM), GW9662 (Cayman
Chemicals, 1 µM), cell-permeable C3 Transferase (Cytoskeleton,
1 ng/ml, pretreament 4 h), Pertussis toxin (PTX, Biomol, 10 ng/
ml, pretreament 18 h). Unless otherwise specified, inhibitors were
added to cells 30 min prior to addition of LPA to the culture medium on the first incubation.

appropriate conjugated secondary antibodies (Alexa Fluor 555
or 488, Cy3, Molecular Probes-Invitrogen). Nuclei were counterstained with 4′,6-diamidino-2-pheylindole (DAPI, 1:1000,
Sigma-Aldrich). Specificity of the staining was verified by the
appropriate negative control immunoglobulin fraction (see
Fig. 4G, H, Fig. 5F, G). For monolayer NS/PCs, cells were permeabilized with PBS-Tween/0.3% Triton X-100 following PFA
fixation.
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Cell morphology assays
Six- to seven-day-old neurospheres cultured on poly-l-lysine/
laminin-coated slides were placed on the heated stage of an inverted microscope (Olympus) equipped with phase-contrast optics and temperature control. During time-lapse recording, the
plated neurospheres were maintained in 25 mM HEPES-buffered
NBM (pH 7.4) at 37°C and observed continuously using a camera
connected to Axiovision time-lapse software (Carl Zeiss). Various
concentrations of LPA and/or selected inhibitors were applied
during time-lapse recording. To observe reversibility of LPA’s effect, LPA was withdrawn from the culture medium and replaced
by normal 25 mM HEPES-buffered complete medium, followed
by time-lapse recording at indicated times. Images were acquired
using 5 s interframe intervals. The pictures were then assessed for
morphological modifications of plated neurosphere and neurite
retraction. At least three independent experiments were performed for each treatment.

Apoptosis and proliferation assays

RhoA activation assay
Active RhoA was measured using the G-LISA RhoA activation
assay biochem kit (Cytoskeleton, colorimetric assay) according to
the manufacturer’s instructions. Briefly, monolayered NS/PCs
were cultured for two days in NBM supplemented with bFGF and
EGF (20 ng/ml) until they reached 30–50% confluency. Concentration of bFGF and EGF was reduced to 10 ng/ml for one day
and then removed overnight prior to treatment. Cells were
treated or not with LPA 10 µM for 1, 3, 5, 15, and 30 min. Following treatments, cells were rinsed twice with cold PBS, rapidly
scraped, lysed in a cold premixed lysis buffer with protease inhibitor on ice, and centrifuged (1,000 g, 4°C, 1 min). Supernatants were collected and snap-frozen in liquid nitrogen. Some
aliquots were taken for protein concentration measurement. Following adjustment of protein concentration, G-LISA was then
processed according to manufacturer’s kit instruction. The optical density (OD) was read at 490 nm using a 96-well microplate
reader (Bio-Rad).

NS/PC monolayer differentiation
To induce neuronal and astrocytic differentiation, the monolayer NS/PCs were replated onto poly-l-ornithine/laminin4
2
treated wells at 1–5 × 10 cells/cm . Medium was changed every
second day, and cells were cultured for three weeks.

NS/PCs were seeded onto laminin-precoated 24-well plates in
NBM supplemented with growth factor (bFGF and EGF, 20 ng/ml
each). After two days, medium was changed and supplemented
with LPA and fixed in PFA 4% 18 h later.

Cell morphology assays of the differentiated neurons
derived from monolayer NS/PC culture
Neurons cultured for three weeks on poly-l-lysine/laminincoated slides were placed on the heated stage of an inverted microscope (Olympus) equipped with phase-contrast optics and
temperature control. During time-lapse recording, the plated
neurons were maintained in 25 mM HEPES-buffered NBM (pH
7.4) at 37°C and observed continuously using a camera connected to time-lapse software (Axiovision and Olympus IX71).
LPA at different concentrations (0.1, 1, and 10 µM) was applied
during time-lapse recording. Images were acquired using 5 s interframe intervals.

siRNA knockdown of ROCK
Monolayer NS/PCs were passaged into complete NBM media
5
without antibiotic one day before transfection at 2.5–5 × 10 /
well in 6-well plates. Knockdown of ROCKI and/or ROCKII
was performed using Dharmacon SMART pool ON-TARGETplus ROCK1 siRNA (L-003536-00-0005) and ON-TARGETplus
ROCK2 siRNA (L-004610-00-0005), which were already demonstrated to be specific in hESC (47). Control for transfection was
done using ON-TARGETplus NonTargeting Pool (D-00181010-05). Specific siRNA (25 nM) for each pool was mixed with
Dharmafect II, following Dharmacon siRNA Transfection’s protocol. Measurement of knockdown efficiency and survival were
respectively performed at 48 h and 72–96 h following transfection. Quantification of ROCKI and ROCKII mRNA levels were
determined by qPCR. Expression levels of corresponding genes
were normalized to the housekeeping gene ␤-actin and expressed as the percentage level over the control. At 48 h post
transfection, cells were passaged onto laminin-coated chamber
slides. At 72 h post transfection, LPA (10 M) was added for 18 h
prior to TUNEL assay.

Statistical analysis
All sets of experiments were performed at least three times in
triplicate, unless specified (n refers to the number of independent experiments performed on different cell cultures). Datasets
were expressed as means ± SEM. Significance of the differences
was evaluated using the t-test or the one- and two-way ANOVA
followed by the Newman-Keuls test for multiple comparisons.
Statistical significance was established at *P < 0.05, **P < 0.01,
and ***P < 0.001.

RESULTS
Neural differentiated hPSCs express LPA1–5 and LPA
producing enzymes mRNA
We performed qPCR analysis of hPSCs at the different
stages of progressive neural differentiation (undifferentiated cells, noggin-treated cells, and neurospheres) to
characterize their expression profile (Fig. 1). All of the
undifferentiated and the differentiated hPSCs expressed
LPA1–5, ATX, and sPLA2 mRNA (Fig. 1), with LPA2 and
LPA modulates human neural progenitor cells

1195

Downloaded from www.jlr.org at Univ of Wollongong (CAUL), on December 7, 2017

Cell apoptosis was quantified by measuring numbers of condensed nuclei with terminal transferase dUTP nick end labeling
(TUNEL) immunocytochemistry. TUNEL analysis was performed
using the In Situ Cell Death Detection Kit (Roche) following the
manufacturer’s instruction. Proliferation was assessed by staining
with Ki67 (Thermo Fisher Scientific, Clone SP6). Briefly, day 7
neurospheres were collected, manually dissociated, centrifuged
onto glass slides (4 min at 1,000 rpm, Shandon Cytospin 4,
Thermo Fisher Scientific), air dried, fixed with 4% PFA, and permeabilized with 0.1% Triton X-100 before immunostaining with a
TMR Red-conjugated TdT enzyme or Ki67, respectively. Apoptosis and proliferation were also assessed on laminin-plated, twoweek-old neurospheres treated with or without LPA (10 M, 18 h)
as described in Ref. 39. Cell nuclei were counterstained with
DAPI. Specificity of the staining was verified by the absence of
staining in negative controls without the TdT enzyme or negative
isotype. Apoptosis and proliferation were respectively quantified
by manually counting TUNEL-positive cells and Ki67-positive cells
as a percentage of total cell number, counting at least 1,000 cells
per treatment by using Image J software (National Institutes of
Health).

LPA treatment in the maintenance of monolayer
NS/PC culture
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LPA4 mRNA being the most abundant. LPA5 mRNA was
expressed at very low levels in neurospheres obtained from
all lines relative to LPA1–4 (Fig. 1A–C). To examine the
expression profile of LPA receptors, ATX, and sPLA2 at
each differentiation stage, the mRNA expression levels of
each gene were presented in comparison to their corresponding levels in undifferentiated hPSCs (Fig. 1D–F).
Fig. 1D provides an illustration of the data obtained with
iPS1. Temporal upregulation of LPA1 mRNA expression
was found during early differentiation (noggin-treated stage),
followed by a downregulation during later differentiation
1196
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(neurosphere stage). Similarly, an increase of ATX mRNA
expression was observed in both noggin-treated cells and
neurospheres. LPA3 and LPA5 mRNA were downregulated
upon neural differentiation, and no significant modulation was observed for LPA2 and LPA4. Very low levels of
sPLA2 were observed at all stages of differentiation. Similar
trends were observed in the other lines tested (Fig. 1E, F).
Given the similar trend of expression of LPA1–5, ATX, and
sPLA2 mRNA in neurospheres from the two clones of iPSCs,
we assessed most biological effects of LPA in iPS1 and compared them with hESCs.

Downloaded from www.jlr.org at Univ of Wollongong (CAUL), on December 7, 2017

Fig. 1. LPA1–5, ATX, and sPLA2 gene expression profile in neural differentiated hPSCs. (A–C) mRNA ex⫺⌬⌬Ct
) profile of LPA1–5, ATX in neurosphere relative to LPA5, in iPS1 (A), iPS2 (B), and hESCs
pression (2
(C). (D–F) mRNA profile of undifferentiated and progressively differentiated into NS/PCs (noggin-treated
and neurosphere) relative to undifferentiated iPS1 (D), iPS2 (E), and hESCs (F). The mRNA expression
levels were normalized against the level of GAPDH mRNA (⌬Ct) with the level of LPA5 (A–C) or LPA1–5, ATX,
and sPLA2 of the undifferentiated hPSCs (D–F) used as the reference genes (⌬⌬Ct). Data were obtained
from at least three independent experiments and expressed as means ± SEM of triplicates of each sample.
The statistical analysis was established by one-way ANOVA; *P < 0.05; **P < 0.01; ***P < 0.001.
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LPA inhibits neurosphere formation through activation
of the Rho/ROCK pathway
We previously reported that one dose of LPA (10 µM)
significantly inhibits neurosphere formation of hESC-derived NS/PCs, without further description of this effect
(39). Here, we observed a similar effect in two clones of
iPSCs and characterized this in both iPSCs and hESCs
(Figs. 2 and 3). Interestingly, LPA-mediated inhibition of

neurosphere formation is dose dependent in iPS1 and
hESCs and shows a similar trend in iPS2, although not statistically significant (Figs. 2C and 3A, F). As exemplified in
Fig. 2A–C in iPS1, LPA strongly inhibited sphere formation in a dose-dependent manner (LPA, 10 µM: 10.4 ±
3.8% of sphere formation compared with control: 59.4 ±
7.5%, n > 3, P < 0.001; Fig. 2A–C). This effect was associated with a decrease in proliferation (36.11 ± 10.1% of
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Fig. 2. LPA inhibits neurosphere formation of hPSC-derived NS/PCs. Representative images of neurosphere in the absence (A) or presence of LPA (10 µM, B) for seven days. (C) Quantification of neurosphere formation in the absence (Control) or presence LPA at various
concentrations. (D) Quantification of proliferation (Ki67) and apoptosis (TUNEL) in neurospheres treated or not (Control) with LPA (10 µM)
and/or Y27632 (1 µM) for seven days. (E–I) Quantification of neurosphere formation in the absence (Control) or presence of LPA (10 µM)
and/or Ki16425 (10 µM, E), GW9662 (1 µM, F), C3 (1 ng/ml, G), Y27632 (1 µM, H), and PTX (10 ng/ml, I). The specific inhibitors were
preincubated as specified in Materials and Methods prior to LPA addition and maintained in the culture medium for the entire differentiation period. Data are expressed as mean ± SEM from at least three independent experiments. The statistical analysis was established by
one-way ANOVA analysis (C–I); *P < 0.05; **P < 0.01; ***P < 0.001. Data presented were obtained with iPS1. Scale bar: 200 µm.
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same time, which cannot be controlled in three-dimensional neurospheres. The adherent monolayered culture
expressed the NS/PC marker nestin (Fig. 4A, B), could be
subcultured for several passages, reformed neurospheres
in suspension culture (Fig. 4C), could be differentiated
into neurons and glial cells (Fig. 4D–F) and also express
mRNA for LPA receptors and producing enzymes (Fig. 4I).
Similar trends in LPA-mediated effects were observed between suspension culture and adherent culture of NS/
PCs, thus allowing parallel conclusions to be made between
the two culture systems (Fig. 4J–M). Adherent NS/PCs were
cultured in the presence or absence of LPA, followed by Rho
activation measurements by ELISA. A basal level of Rho activation was detected on control NS/PCs. As shown in Fig. 4N,
LPA induced a rapid increase of active RhoA (GTP-Rho)
in NS/PCs, which was biphasic with an elevation that
peaked at 1 min post exposure followed by a sustained but
lower activity for at least 30 min. This result directly demonstrates that LPA stimulates Rho in NS/PCs and that this
activation critically modulates NS/PC expansion.
To exclude potential off-targets of the ROCK kinase inhibitor Y27632 despite its high specificity, we further confirmed our results by a molecular approach consisting of
knocking down ROCKI and ROCKII by siRNA in monolayered NS/PCs, individually or together (Fig. 4O, P). Following 48 h post transfection, single siRNA treatment for either
ROCKI or ROCKII specifically knocked down its corresponding gene while their dual knocking down resulted in 75.6 ±
7.0% and 76.2 ± 4.3% downregulation of ROCKI and ROCKII
mRNAs (Fig. 4O). When monolayered NS/PCs were knocked
down for both ROCKI/ROCKII, the apoptosis induced by
LPA was abolished, demonstrating the involvement of ROCK
in LPA’s effect (Fig. 4P).

LPA induces RhoA activation
To confirm that LPA modulated NS/PC expansion by
activation of the Rho/ROCK pathway, we measured Rho
activity in NS/PCs by using an adherent culture of human
NS/PCs derived from dissociated neurospheres. This protocol was favored over spheres, as the monolayer NS/PC
culture ensures an even exposure of LPA to all cells at the

LPA induces morphological rearrangements of hPSCderived early neurons through the Rho/ROCK pathway
After six days of plating, neurospheres had already given
rise to ␤III-tubulin-positive early neurons, which radially
migrate out from the edges of the neurospheres (Fig. 6).
When incubated with LPA, these early neurons underwent
rapid neurite retraction, leading to cell rounding (occurs
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LPA inhibits the neuronal differentiation of iPSCs
through the Rho/ROCK and PI3K/Akt pathways
LPA did not modify glial differentiation of iPSC-derived
neurospheres but inhibited their neuronal differentiation
(Fig. 5A–G). This effect was dose dependent and ROCK
and PI3K/Akt dependent (Fig. 5H, I). As shown in Fig. 5I,
LPA’s effect on human iPSC-derived NS/PCs was partially
abolished by the sole application of Y27632 or LY294002
but was abolished in the presence of both inhibitors. These
effects were observed in both iPSC lines tested. As previously observed with hESC-derived neurospheres (39), we
confirm here that LPA acts through an inhibition
of differentiation rather than by modifying proliferation or
apoptosis of these two-week-old neurospheres. Indeed,
neurospheres plated onto laminin in the presence of LPA
(10 µM, 18 h) did not show modification of Ki67 or TUNEL
when compared with control conditions (no LPA; Fig. 5J).
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Ki67-positive cells in LPA-treated cells versus 64.67 ± 5.84%
in control conditions, n > 3, P < 0.01; Fig. 2D) as well as an
increase in apoptosis (LPA: 69.86 ± 9.1% of cells were
TUNEL-positive versus 40.03 ± 5.9% in control, n > 3, P <
0.01; Fig. 2D). A similar trend was observed in hESCs, although the decreased proliferation was not found to be
statistically significant (Fig. 3J).
Quantifying neurosphere formation frequency does
not discriminate between apoptosis and proliferation but
provides a reliable and robust measurement of NS/PC expansion and was used here to identify the signaling mechanisms used by LPA during this process. The impact of LPA
on neurosphere formation was found not to be mainly
through its extracellular receptors LPA1/3, as pretreatment
with Ki16425 at a dose that is specifically antagonistic to
LPA1/3 (48) did not modify LPA-mediated inhibition of
sphere formation in the iPSCs but significantly reduced the
effect of LPA on hESC sphere formation (Figs. 2E and 3B,
G). It is likely that the blockage of these receptors is compensated by the other LPA receptors present in NS/PCs. Due to
the lack of commercially available, specific LPA receptor antagonists, the involvement of the other receptors was not assessed in this study. Further, we decided not to use siRNA in
these experiments because of the poor transfection efficiency due to the three-dimensional structure of the sphere.
Instead, siRNA knockdown of ROCKI/II were performed on
monolayered NS/PCs as explained below. In the presence of
the selective PPAR␥ antagonist GW9662 (49), the effect of
LPA was not modified, suggesting that LPA does not act
through PPAR␥ to inhibit neurosphere formation (Fig. 2F).
In all cell lines, the effect of LPA on sphere formation
was abolished by pretreatment with either the specific Rho
inhibitor C3 exoenzyme (50) (Figs. 2G and 3C, H) or with
the p160 ROCK inhibitor Y27632 used at a dose specific to
p160ROCK inhibition (51) (Figs. 2H and 3D, F), which
alone have no marked effect, indicating that LPA acts
through the Rho/ROCK pathway to inhibit neurosphere
formation. Furthermore, when cells were incubated with
PTX, which ADP-ribosylates ␣i proteins, LPA’s effect was
maintained (Figs. 2I and 3E, I), suggesting that LPA’s effect is not Gi/o mediated and is consistent with a G12/13
Rho-mediated mechanism. This data was confirmed by
measuring apoptosis and proliferation of NS/PCs in the
presence of LPA and Y27632 (Figs. 2D and 3J). The sole
application of Y27632 did not modify basal proliferation
or apoptosis (Figs. 2D and 3J). As shown in Fig. 2 in iPS1,
LPA-induced apoptosis and LPA-reduced proliferation
were abolished by Y27632 (Fig. 2D). Thus, this data indicate that LPA acts through the Rho/ROCK pathway to inhibit neurosphere formation, at least by increasing cell
apoptosis and by decreasing proliferation in iPS1.
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Fig. 3. LPA inhibits neurosphere formation of iPS2- and hESC-derived NS/PCs. Quantification of neurosphere formation in the absence
(Control) or presence of LPA at various concentration in iPS2 (A–E) and hESCs (F–I), with or without Ki16425 (10 µM, B, G), C3 (1 ng/ml,
C, H), Y27632 (1 µM, D, F), and PTX (10 ng/ml, E, I). (J) Quantification of proliferation (Ki67) and apoptosis (TUNEL) in hESC neurospheres treated or not (Control) with LPA (10 µM) and/or Y27632 (1 µM) for seven days. The specific inhibitors were preincubated as
specified in Materials and Methods prior to LPA addition and maintained in the culture medium for the entire differentiation period. Each
panel represents a pool of at least three independent experiments, and data are expressed as means ± SEM. The statistical analysis was established by one-way ANOVA analysis; *P < 0.05; **P < 0.01; ***P < 0.001.
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DISCUSSION
LPA is bioactive lipid known to affect most cell types of
the nervous system. Limited studies have addressed LPA’s
role in the human CNS and in human neural cells. We
previously described that LPA inhibits the neuronal differentiation of hESC-derived NS/PCs and briefly reported
that LPA inhibits neurosphere formation of hESCs (39).
Here we established a comprehensive in vitro system to
assess the role of LPA at multiple stages of human neural
differentiation using both hESCs and human iPSCs. We
assessed whether these two different sources of human
NS/PCs are equivalent in terms of LPA’s effects upon neuralization by describing LPA1–5, ATX, and sPLA2 mRNA
expression and by assessing whether effects previously
observed with hESCs were retrieved in human iPSCs. We
also characterized how LPA modifies NS/PC expansion
and the morphology of early human neurons. We observed
a similar pattern of effects of LPA throughout the neural
differentiation of hESCs and iPSCs. The three lines tested
expressed LPA receptors and ATX and sPLA2 mRNA with
a similar profile. In all NS/PCs tested, LPA increased cell
death and inhibited neuronal differentiation without
modifying glial differentiation. Furthermore, LPA induced
morphological rearrangements in early neurons differentiated from NS/PCs. In iPSC-derived NS/PCs, LPA also
significantly decreased proliferation, while a similar trend
was observed in hESC-derived NS/PCs but without reaching statistical significance. Hence, our data shows generally
consistent results across different iPSC and hESC lines,
with some minor interline differences in responsiveness to
1200
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LPA, indicating that the mechanisms mediated by LPA are
fundamental in neural differentiation and are not influenced by other variables often observed between different
hESC/iPSC lines (53).
Our results show that both undifferentiated hPSCs and
neural differentiated hPSCs express LPA1–5 mRNA, confirming our previous RT-PCR data (8, 39, 54), and they show
that LPA2 and LPA4 are the most abundant mRNA in undifferentiated hPSCs and neurospheres. Modulation in the
receptor expression profile was observed following neural
differentiation with an upregulation of LPA1 mRNA during
the early neural commitment of hPSCs (noggin-treated
stage), followed by its downregulation during later differentiation (neurosphere stage). The mRNA expression profile
in hPSC-derived neurospheres shared some similar trends
to the profile observed in hESC-derived NEP (41) and in
the monolayer NS/PCs, with LPA1,2,4 being the most expressed mRNA. The low level of sPLA2 expression and the
presence of ATX mRNA following neural differentiation, as
exemplified in this data, are consistent with the fact that
ATX expression is associated with neurogenesis (55).
As LPA1 shows its highest expression level at the noggin stage, we assessed its involvement in neurosphere
formation as readout of the impact of LPA on NS/PC
expansion. Using the LPA1–3 antagonist Ki16425, we observed no significant effect of this treatment on LPA’s effect in iPSCs and a partial inhibition in hESCs, suggestive
that other receptors are involved in the inhibition of NS/
PC expansion by LPA. This is consistent with the fact that
LPA2,4 are the most abundant mRNAs in NS/PCs from all
cell lines. LPA receptors are coupled to multiple G proteins, with LPA1–5 coupled to Gq, LPA1,2,4,5 coupled to G12,
LPA1–4 coupled to Gi, and LPA4,5 also coupled to Gs (1).
PTX did not affect LPA’s effect on sphere formation, suggesting that LPA acts independently of ␣i, either through
G12 and/or Gq and/or the ␤␥ subunits of G proteins. This
is highly likely given that the main receptors present at
either the noggin stage or neurosphere stage (LPA2, 4 > 1)
signal through Gq and G12. Additionally, as LPA’s effect
on NS/PC expansion is Rho/ROCK-mediated, it is also
probable that the mechanism is G12 dependant (56). Further, we showed that LPA inhibits neuronal differentiation of iPSC-derived NS/PCs through the PI3K/Akt and
Rho/ROCK pathways, which are likely to be mediated
by ␤␥ and G12, respectively (56), and which is consistent
with our previous data obtained with hESCs (39). Lastly,
we describe that LPA induces morphological rearrangements of early neurons in a Rho/ROCK manner, presumably mediated by G12. Altogether, this data demonstrates
the importance of LPA receptor-mediated signaling along
the whole neural differentiation process.
We found that LPA promoted apoptosis of early human
NS/PCs, as revealed by neurosphere formation assay,
which is consistent with some NS/PC and neuroblast studies performed in rodents (16, 17, 38, 57, 58) but differs
with others in which LPA improves cell survival (16, 38) or
proliferation (13, 35, 59). In human cells, we previously
showed that LPA does not modify apoptosis of older hESCderived NS/PCs (39) as, when two-week-old hESC-derived
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within minutes; Fig. 6A–D and supplementary video I).
These effects were dose dependent, starting at 1 µM, and
reversible (Table 1 and Fig. 6E–G). The reversibility took
longer when compared with the rapid retraction observed
in the presence of LPA, but it suggest that the neurite retraction was not the result of cell death.
LPA-induced morphological rearrangements could be
prevented by preincubation with C3 exoenzyme or Y27632
(Table 1, Fig. 6H–K, and supplementary video I), indicating that LPA acts through the Rho/ROCK pathway to induce neurite retraction in early neurons derived from
hPSCs. PTX and LY294002 had no effect on LPA-induced
neurite retraction (Table 1), indicating that this mechanism is G␣i and PI3K/Akt independent. Similar data were
observed in early neurons derived from monolayered NS/
PC cultures (Fig. 4K, L). To further elucidate LPA’s role in
neural development, we analyzed the impact of LPA on
the actin-myosin cytoskeleton, assessing cofilin and MLC,
respectively, as these proteins are downstream effectors of
ROCK (52). These experiments were performed on monolayered NS/PCs by immunohistochemistry to assess localization of phospho-cofilin and phospho-MLC. As shown in
Fig. 6L–O, although we did not observe an effect of LPA
on phospho-cofilin, LPA induced the phosphorylation of
MLC, suggesting that it induces morphological rearrangements through modification of myosin.

Supplemental Material can be found at:
http://www.jlr.org/content/suppl/2013/03/04/jlr.M032284.DC1
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neurospheres plated in conditions allowing differentiation
were incubated with LPA for 18 h, no modification in apoptosis or proliferation was detected by TUNEL or BrdU assays,
respectively (39). Here we confirmed this data using human
iPSC-derived neurospheres. Further, others demonstrated
that LPA increases growth of hESC-derived NEP (41), an effect observed at a concentration of up to 0.1 µM. In this study,
that concentration already inhibited sphere formation but
did not significantly affect monolayered NS/PCs. Similarly,
LPA inhibits neuronal differentiation but not glial differen-

tiation of human iPSCs, which is in agreement with our previous study using hESCs (39) and with data obtained in rodents
(58); although other studies found opposite effects in various
NS/PCs and neuroblasts (14, 17, 18, 38, 59, 60).
Even though using similar protocols of maintenance of
NS/PCs as monolayers, it is interesting to note that we observe some variations with data obtained on hESC-derived
NEP (41). In particular, as shown in Fig. 4, we did not
observe the growth effect of low doses of LPA on monolayers of NS/PCs described by others (41), but we showed
LPA modulates human neural progenitor cells
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Fig. 4. Characteristics of adherent NS/PC in culture. (A–F) Representative images of plated NS/PCs showing brightfield (A) and immunostaining for nestin (red) and DAPI (blue, B). (C) Representative brightfield image of a neurosphere formed from plated NS/PCs.
(D–F) Representative immunostaining of NS/PCs differentiated into neurons with ␤III-tubulin (green, D), DCX (red, E), and glial cells
⫺⌬⌬Ct
)
with GFAP (red, F) and DAPI counterstain (blue). (G) Rabbit and (H) mouse negative isotype controls. (I) mRNA expression (2
profile of LPA1–5, ATX, and sPLA2 in NS/PCs. For LPA1–5 and ATX mRNA, expression levels were normalized against the level of GAPDH
mRNA (⌬Ct) with the level of LPA5 used as the reference gene (⌬⌬Ct); sPLA2 was expressed compared with undifferentiated cells to show
its very low level of expression. (J) Quantification of proliferation (Ki67) and apoptosis (TUNEL) in plated NS/PCs treated or not (Control) with various doses of LPA (0.1–10 µM) for 18 h. (K, L) Representative images of early neurons from monolayered NS/PCs cells prior
to treatment (K) and treated with LPA (10 µM) for 20 min (L) showing morphological rearrangements. (A–H, K, L) Data are representative pictures of at least three independent experiments. Scale bars are indicated within each image. (M) Quantification of apoptosis
(TUNEL) in plated NS/PCs treated or not (Control) with LPA (10 µM) and/or Y27632 (1 µM) for 18 h. (N) Time course of activated RhoA
(GTP Rho) by LPA measured at 490 nm by ELISA in monolayered NS/PCs. (O) mRNA expression profile of ROCKI and ROCKII following
knockdown of ROCKI and/or ROCKII by siRNA for 48 h. mRNA expression levels were normalized against the level of ␤-actin mRNA and
are expressed as percentage of control. (P) Quantification of apoptosis (TUNEL) in siRNA control pool (Control, LPA) or ROCK I- and
ROCK II-treated monolayer NS/PCs subsequently incubated in the absence or presence of LPA (10 µM) for 18 h. (I, J, M–P) Data were
obtained from at least three independent experiments and are expressed as means ± SEM of triplicates of each sample. The statistical analysis was established by one-way ANOVA; *P < 0.05; **P < 0.01; ***P < 0.001.
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Fig. 5. LPA inhibits neuronal differentiation of human iPSCs without modifying apoptosis and proliferation. (A–C) Immunostaining of
glial differentiation of neurospheres plated onto fibronectin and incubated in the presence of LPA (five days, 10 µM) with GLAST (A),
GFAP (B), or A2B5 (C) antibodies with DAPI counterstain (blue). (D, E) ␤III-tubulin immunostaining (red) and DAPI counterstain (blue)
of neurospheres plated onto laminin and incubated in the presence of LPA (five days, 10 µM, D) or in its absence (E). (F) Mouse and (G)
rabbit negative isotype controls. Data are representative pictures of at least three independent experiments. Scale bars: A–C, F–G: 20 µm;
D, E: 100 µm. (H, I) The percentage of neuron-forming neurospheres was quantified in the presence of various concentrations of LPA (H)
or in the absence (Control) or presence of LPA (10 µM) and/or Y27632 (1 µM) and/or LY 294002 (10 µM) (I). (J–L) Proliferation and
apoptosis by Ki67 and TUNEL quantification, respectively, of two-week-old neurospheres plated onto laminin in the absence (Control) or
in the presence of LPA (10 µM) for 18 h in iPS1 (J), iPS2 (K), and hESCs (L). (H–L) Data are expressed as means ± SEM of at least three
independent experiments. The statistical analysis was established by one-way ANOVA analysis (H, I) or t-test (J–L); *P < 0.05; **P < 0.01;
***P < 0.001. (A–J) Data presented were obtained with iPS1.
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that LPA induces apoptosis of the monolayer NS/PCs at a
dose that was not previously tested in hESC NEP. Our data,
using two different sources of human NS/PCs and two different protocols for maintenance (neurospheres and monolayers), indicates that the observed pro-apoptotic effects of
LPA are consistent, regardless of the NS/PC origin. It is
thus likely that the variations between our data and those of
Hurst and colleagues in terms of cell growth at low concentrations of LPA are due to a difference in the populations of
human cells studied. In particular, the main difference between the protocols for generating a monolayer of NS/PCs
is in the derivation of the NS/PCs themselves. We use dissociated neurospheres to obtain a monolayered culture,
whereas the NEP used by Hurst and colleagues were directly
obtained from hESCs without going through a neurosphere
stage (41, 46). This variation in protocol might account for

the discrepancies in LPA-mediated effects between the studies, which could reflect a variation in the developmental
state (either more or less restricted) of the human NS/PC
populations in use.
LPA has been extensively studied for its prominent effect
in inducing cytoskeletal rearrangements. In particular, LPA
is shown to induce neurite retraction and cell rounding
through the Rho/ROCK pathway in rodent immortalized
neuroblasts and PC12 (26, 61). We observed a similar pattern
of morphological changes in early human neurons, which,
following exposure to LPA, underwent immediate and rapid
retraction, cell rounding, and migration to form cell clusters
and compaction in a Rho/ROCK-dependent manner. Interestingly, in hESC NEP, LPA induced ROCK-dependent morphological rearrangements, but these were observed to be
slow, peaking around 5 h (41).
LPA modulates human neural progenitor cells
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Fig. 6. LPA induces morphological rearrangements in early neurons derived from hPSCs. Representative images of cells prior to treatment (0, A, E) and treated with LPA (10 µM) for 1, 5, and 10 min (1′, 5′, 10′, C–D); or treated with LPA (10 µM) for 10 min (F) and then
incubated with normal medium for 18 hrs (G); or preincubated with C3 (1 ng/ml, H) or Y27632 (1 µM, J), prior to addition of LPA
(10 µM, I, K) for 10 min. Data presented were obtained with iPS1. Square shows example of an area showing retractions. Scale bar: 100 µm.
(L–O) Representative immunostained images of early neurons in control or following LPA treatment (10 µM, 15 min) with phospho-cofilin
(L, M) or phospho-MLC antibody (N, O) and DAPI counterstain (blue).
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TABLE 1.

Neurite retraction in early neurons derived from hPSCs

Tested Agents

Control
LPA 0.1 µM
LPA 1 µM
LPA 10 µM
Y27632 1 µM
Y27632 + LPA 10 µM
C3
C3 +LPA 10 µM
PTX
PTX + LPA 10 µM
LY294002
LY294002 + LPA 10 µM

Neurite Retraction (+/⫺)

⫺
⫺
+
+
⫺
⫺
⫺
⫺
⫺
+
⫺
+

LPA’s effect in neurite retraction among tested agents in human
NS/PCs. Early neurons differentiated from hPSCs were incubated or not
with LPA and/or Y27632 (1 µM, 30 min preincubation), C3 transferase
(1 ng/ml, 4 h preincubation), PTX (10 ng/ml, 18 h preincubation), and
LY 294002 (10 µM, 30 min preincubation). +, retraction; ⫺, no retraction.
Each treatment assessment is representative of at least three independent
experiments.
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CONCLUSION
LPA plays a broad role in human NS/PCs and their neural derivatives, regulating expansion, differentiation, and
morphology. We showed that in hPSC-derived NS/PCs,
LPA increases apoptosis, decreases proliferation, inhibits
neuronal differentiation, and induces rapid morphological
rearrangements in early neurons. All these effects are at
least Rho/ROCK dependent. We observed that the effects
of LPA on NS/PCs are insensitive to PTX treatment, indicating no involvement of ␣i but suggestive of the involvement
of ␣12, ␣q, or ␤/␥ in these biological effects. LPA-induced
activation of Rho/ROCK is likely to be G12 mediated, as this
is the common upstream G protein for Rho and has been
reported to be involved in the pro-apoptotic effect of LPA
through LPA1,2,4 (16). Thus, our data demonstrate the consistency in the effect of LPA across various sources of human NS/PCs, rendering hESCs and human iPSCs valuable
in vitro models for studying lysophospholipid signaling in
human neural cells. Our data also highlight the importance
of the Rho/ROCK pathway in human NS/PC expansion
and differentiation. It is thus possible that blocking LPA signaling in vivo, in which levels increase following trauma,
would enhance neurogenesis.
The authors thank Guizhi Sun and Daniella Herszfeld (Monash
University) for their help in setting up monolayer cultures of
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The importance of the Rho/ROCK pathway in stem
cell survival is now established. The ROCK inhibitor
Y27632 significantly increases hESC single-cell survival
(62, 63) and NS/PCs following neurosphere dissociation
(64). Further, upon dissociation to single cells, the Rho/
ROCK pathway is activated and responsible for modulating cell-cell contact-induced apoptosis in hESCs (65),
NS/PCs (64), and neurons (66), an effect associated with
MLC phosphorylation in hESCs (47). Moreover, in neurons, Rho/ROCK activation induces apoptotic membrane
blebbing by stimulating MLC phosphorylation (66) and
has associations to neuronal death following spinal cord
injury (67). Other data suggest that ROCK inhibition
may not act directly by reducing apoptosis but rather by
desensitizing cells to their environment and thus limiting apoptosis (68).
Our data showing LPA’s activation of RhoA is in line
with data obtained by others in other stem and progenitor
cells (1) and are the first demonstration of human-derived
NS/PCs at various stages of differentiation. A large body of
evidence shows that LPA acts through the Rho pathway to
modify cell survival, apoptosis, and proliferation in diverse
types of cells by mediating cell shape/focal adhesion alteration (38, 69, 70). Our current data demonstrate that
LPA activates RhoA in human NS/PCs and implicate this
pathway in LPA-induced apoptosis, decreased proliferation, and together with the PI3K/Akt pathway, LPA inhibition of neuronal differentiation of human NS/PCs.
Furthermore, activation of this pathway is essential to LPAinduced morphological rearrangements in human NS/
PC-derived early neurons.
Adult NS/PCs are present in the CNS, predominantly in
neurogenic regions, such as the subventricular zone and
hippocampus. They have been reported to migrate to sites
of injury and tumors (71), effects likely to be linked to the
repair of damaged tissue. Furthermore, evidence suggests
that NS/PCs contribute to neurogenesis in the adult
mouse and human following stroke (72, 73). Similar data
were observed following brain injury in the juvenile rat

(74). Following CNS injury, ischemia, or events that damage the blood brain barrier, LPA-like activity increased
within the cerebrospinal fluid, levels of LPA within the
CNS increased up to 10 µM (75–78), and levels of ATX
increased within astrocytes neighboring a lesion of the
adult rat brain (79). Our data using human cells suggest
that the presence of LPA in regions of neurogenesis within
the CNS may modify NS/PC survival and differentiation.
Our data also suggest that high levels of LPA have the ability to be pro-apoptotic on human NS/PCs, to bias their
differentiation toward glial cells and to induce neurite retraction and cell rounding of early neurons and thus limit
the regenerative responses to injury. This is relevant to endogenous neurogenesis and might explain low levels of
neurogenesis observed following trauma, with LPA being
a limiting factor of genesis. This finding is also relevant to
transplantation of human stem or progenitor cells within
the CNS, as the inflammation present or generated by the
transplantation procedure itself may induce increased levels of LPA which could limit neurogenesis and repair. Our
data also suggest that neurogenesis may be enhanced by
blockers of LPA signaling, such as LPA antibodies that we
recently demonstrated were able to abolish LPA’s effect
on human NS/PCs in vitro and improve neuronal survival
and functional recovery following spinal cord injury in
vivo (80). Such a mechanism has already been proved with
sphingosine-1-phosphate, as blocking its signaling enhances endogenous NS/PC migration to the injury site
following trauma (81).
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NS/PCs; Dr. Hitesh Peshavariya and Dr. Guei-Sheung Liu
(Centre for Eye Research Australia) for their advice with siRNA
work; and Prof. James A. Thomson (University of Wisconsin)
for providing the iPS(Foreskin) cell lines.
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